A phase I study of selective cyclin dependent kinase inhibitor P1446A-05 administered on an intermittent schedule in patients with advanced refractory tumors

被引：0
|
作者：
Gupta, Sudeep
Jain, Minish Mahendra
Maru, Anish
Nag, Shona Milon
Somani, Naresh
Mehta, Ajay O.
Kulkarni, Sujay
Acharya, Shivani Anil
Dhobe, Poornima
Jadhav, Nitin
机构：
[1] Tata Mem Hosp, Bombay, Maharashtra, India
[2] Ruby Hall Clin, Pune, Maharashtra, India
[3] SEAROC Canc Ctr, Jaipur, Rajasthan, India
[4] Jehangir Clin Trials Dev Ctr, Pune, Maharashtra, India
[5] Bhagwan Mahaveer Canc Hosp & Res Ctr, Jaipur, Rajasthan, India
[6] Cent India Canc Res Inst, Nagpur, Maharashtra, India
[7] Piramal Healthcare Ltd, Bombay, Maharashtra, India
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3011
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors
    Schwartz, Gary K.
    Carvajal, Richard D.
    Midgley, Rachel
    Rodig, Scott J.
    Stockman, Paul K.
    Ataman, Ozlem
    Wilson, David
    Das, Shampa
    Shapiro, Geoffrey I.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (02) : 370 - 380
  • [32] Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors
    Gary K. Schwartz
    Richard D. Carvajal
    Rachel Midgley
    Scott J. Rodig
    Paul K. Stockman
    Ozlem Ataman
    David Wilson
    Shampa Das
    Geoffrey I. Shapiro
    Investigational New Drugs, 2013, 31 : 370 - 380
  • [33] A dose escalation, pharmacokinetic, and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors
    Mahadevan, D.
    Plummer, R.
    Squires, M. S.
    Rensvold, D.
    Dragovich, T.
    Adams, J.
    Lock, V.
    Smith, D.
    Von Hoff, D. D.
    Calvert, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [34] A phase I study of SHR6390, a cyclin-dependent kinase 4/6 inhibitor in patients with advanced breast cancer (ABC).
    Zhang, Pin
    Xu, Binghe
    Gui, Lin
    Wang, Wenna
    Xiu, Meng
    Zhang, Xiao
    Sun, Guilan
    Zhu, Xiaoyu
    Zou, Jianjun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [35] Phase I Study of the Selective Aurora A Kinase Inhibitor MLN8054 in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Pharmacodynamics
    Macarulla, Teresa
    Cervantes, Andres
    Elez, Elena
    Rodriguez-Braun, Edith
    Baselga, Jose
    Rosello, Susana
    Sala, Gemma
    Blasco, Inma
    Danaee, Hadi
    Lee, Yih
    Ecsedy, Jeffrey
    Shinde, Vaishali
    Chakravarty, Arijit
    Bowman, Douglas
    Liu, Hua
    Eton, Omar
    Fingert, Howard
    Tabernero, Josep
    MOLECULAR CANCER THERAPEUTICS, 2010, 9 (10) : 2844 - 2852
  • [36] Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study
    Xu, Jian Ming
    Wang, Yan
    Chen, Yu Ling
    Jia, Ru
    Li, Jie
    Gong, Ji Fang
    Li, Jing
    Qi, Chuan
    Hua, Ye
    Tan, Cui Rong
    Wang, Jian
    Li, Ke
    Sai, Yang
    Zhou, Feng
    Ren, Yong Xin
    Qing, Wei Guo
    Jia, Hong
    Su, Wei Guo
    Shen, Lin
    ONCOTARGET, 2017, 8 (26) : 42076 - 42086
  • [37] A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors
    Klaus Mross
    Heike Richly
    Annette Frost
    Dirk Scharr
    Bahar Nokay
    Ralph Graeser
    Chooi Lee
    James Hilbert
    Rainer-George Goeldner
    Oliver Fietz
    Max E. Scheulen
    Cancer Chemotherapy and Pharmacology, 2016, 78 : 405 - 417
  • [38] A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors
    Mross, Klaus
    Richly, Heike
    Frost, Annette
    Scharr, Dirk
    Nokay, Bahar
    Graeser, Ralph
    Lee, Chooi
    Hilbert, James
    Goeldner, Rainer-George
    Fietz, Oliver
    Scheulen, Max E.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (02) : 405 - 417
  • [39] A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors
    Mojun Zhu
    Julian R. Molina
    Grace K. Dy
    Gary A. Croghan
    Yingwei Qi
    James Glockner
    Lorelei J. Hanson
    Michelle M. Roos
    Angelina D. Tan
    Alex A. Adjei
    Investigational New Drugs, 2020, 38 : 1755 - 1762
  • [40] A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors
    Zhu, Mojun
    Molina, Julian R.
    Dy, Grace K.
    Croghan, Gary A.
    Qi, Yingwei
    Glockner, James
    Hanson, Lorelei J.
    Roos, Michelle M.
    Tan, Angelina D.
    Adjei, Alex A.
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (06) : 1755 - 1762
12345